US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Medline Inc. (MDLN): Largest Cash Raise IPO Since 2021's Rivian Brings End of Year Opportunity

Medline Inc. (MDLN): Hospital Product & Supply Chain Company Sets Terms on Mega IPO, $5b+ Cash Raise

Medline Inc. (MDLN): Peeking at the IPO Prospectus of Mega Hospitals Product & Supply Chain Company

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Medline delivered a blockbuster debut, surging over 40% from issue to close, marking the largest and strongest IPO performance of 2025.</li>
<li>An upsized, heavily oversubscribed offering and powerful aftermarket trading signal deep institutional conviction and durable demand.</li>
<li>The deal positions Medline as a flagship IPO and a momentum-setting springboard for investor confidence heading into 2026.</li>
</ul>


Medline delivered a blockbuster debut, surging over 40% from issue to close, marking the largest and strongest IPO performance of 2025.
An upsized, heavily oversubscribed offering and powerful aftermarket trading signal deep institutional conviction and durable demand.
The deal positions Medline as a flagship IPO and a momentum-setting springboard for investor confidence heading into 2026.


Medline Inc. (MDLN): Blockbuster Debut Caps 2025 With a Statement Win